医疗设备与数字健康企业ResMed（RMD）周二股价上涨近 5%，此前加拿大皇家银行资本市场将该股评级由 “行业表现” 上调至 “跑赢大盘”。
该机构同时将目标价从 244 美元上调至 262 美元，相较当前 229 美元的股价，潜在上行空间达 17%。ResMed主打睡眠呼吸暂停以及其他呼吸疾病治疗设备，8 月刚刚公布亮眼的第四季度财报，核心睡眠设备板块销售额超出市场预期。
ResMed “盈利前景向好” 以及 “加大资本管理力度”，是加拿大皇家银行上调评级的主要依据。机构预测，未来数年ResMed可以实现高个位数的盈利增速。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.